Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biome Australia Ltd ( (AU:BIO) ) has provided an update.
Biome Australia has filed its first patent application for a proprietary next generation probiotic strain, BMB18, marking its formal entry into intellectual property-driven growth and differentiated product development. The strain, developed with European research partners and registered with the DSMZ strain bank in Germany, has shown promising pre-clinical properties including immune modulation, intestinal barrier support and antioxidant activity.
The company has secured ethics approval for a randomised, double-blind, placebo-controlled human clinical trial with La Trobe University, expected to begin in Q4 FY26 with 240 participants to build a robust data set on BMB18. Outcomes from this trial are intended to guide future product integration into Biome’s existing pipeline and support a broader IP strategy, leveraging its Activated Probiotics brand and established distribution network for potential commercialisation in the practitioner market.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Ltd is a microbiome health company listed on the ASX that develops and markets probiotic-based solutions targeting specific health needs. Its portfolio, led by the Activated Probiotics brand, focuses on practitioner and mass distribution channels, positioning the company in the growing market for clinically supported, next generation probiotics.
Average Trading Volume: 203,173
Technical Sentiment Signal: Hold
Current Market Cap: A$74.1M
See more data about BIO stock on TipRanks’ Stock Analysis page.